HER-2低表达乳腺癌的研究进展与未来展望  

Research Progress and Future Prospect of HER-2 Low Expression Breast Cancer

作　　者：买吐鲁佰·米尔扎合买提 卡吾力·居买 地力木拉提·艾斯木吐拉[1] 李慧芳[1] 阿力清·阿不都萨拉木 

机构地区：[1]新疆医科大学第一附属医院乳腺外科,新疆 乌鲁木齐

出　　处：《临床医学进展》2023年第10期16593-16601,共9页Advances in Clinical Medicine

摘　　要：近年来对HER-2低表达乳腺的关注,在全球范围日益增加,随着新型靶向药物的研发及检测技术的发展,HER-2低表达乳腺癌与其他类型乳腺癌表现出不同的病理学及临床特征。对于HER-2低表达乳腺癌患者的预后,众多学者持有不同的观点尚无统一论据。本文阐述了近年来HER-2低表达乳腺癌的最新研究进展,重点介绍了HER-2低表达乳腺癌的生物学特性、目前病理实践中免疫组化判定HER-2低表达乳腺癌所遇到的问题,以及对这一新型领域未来的发展做一概述。In recent years, HER-2 low expression breast cancer has received increasing attention. With the development of new HER-2 targeted drugs and detection methods, HER-2 low breast cancer exhibit pathological and clinical features that differ from other types of breast cancer. For the prognosis of HER-2-low expression breast cancer, many scholars hold different views, and there is no unified ev-idence. In this paper, the latest research progress in breast cancer with low HER-2 expression in recent years is reviewed, focusing on the biological characteristics of HER-2 low breast cancer, and the problems encountered in the immunohistochemical detection of HER-2 low expression breast cancer in current pathological practice, and the future development of this new field is summarized.

关 键 词：乳腺癌 人表皮生长因子2 HER低表达 免疫组化 ADC 

分 类 号：R73[医药卫生—肿瘤]